Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 11/20 | 0.52 |
| ▸ | RARG | P13631 | 11/20 | 0.52 |
| ▸ | RARA | P10276 | 10/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 6/20 | 0.41 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.41 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 2/20 | 0.40 |
| ▸ | RXRB | P28702 | 1/20 | 0.40 |
| ▸ | RXRG | P48443 | 1/20 | 0.40 |
| ▸ | HNF4A | P41235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29249339 | 0.92 | RARB (0.61) | RARBRARGRARAALDH1A1MAPK1 | |
| SCHEMBL29249340 | 0.92 | RARB (0.61) | RARBRARGRARAALDH1A1MAPK1 | |
| SCHEMBL2240304 | 0.80 | RARB (0.76) | RARBRARGRARARXRACYP26A1 | |
| Hydrochloric Acid SCHEMBL9133279 | 0.78 | RARB (0.74) | RARBRARGRARARXRACYP26A1 | |
| SCHEMBL23704986 | 0.77 | BACE1 (0.41) | — | |
| SCHEMBL23704772 | 0.75 | RARA (0.49) | RARBRARGRARAALDH1A1MAPK1 | |
| SCHEMBL30058908 | 0.75 | RARA (0.49) | RARBRARGRARAALDH1A1MAPK1 | |
| SCHEMBL23704769 | 0.75 | RARA (0.49) | RARBRARGRARAALDH1A1MAPK1 | |
| SCHEMBL23704969 | 0.75 | RARA (0.49) | RARBRARGRARAALDH1A1MAPK1 | |
| SCHEMBL28347731 | 0.75 | RARA (0.54) | RARBRARGRARAALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. | 2023-05-18 | — | — | US | disclosed |
| CN-115484948-A | Compound and use thereof | 福宏治疗公司 | 2022-12-16 | — | — | CN | disclosed |
| EP-4096657-A1 | COMPOUNDS AND USES THEREOF | Foghorn Therapeutics Inc. (US) | 2022-12-07 | — | — | EP | disclosed |
| WO-2021155316-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
| WO-2021155316-A1 | COMPOUNDS AND USES THEREOF | FOGHORN THERAPEUTICS INC. (US) | 2021-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149414-A1 | COMPOUNDS AND USES THEREOF | VHL, CLN6, TFEB | RARB 140/4885RARG 308/4885RARA 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.